rosiglitazone has been researched along with ns-220 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Bahekar, R; Giri, S; Jain, M; Jamili, J; Makadia, P; Patel, D; Patel, H; Patel, L; Patel, P; Pingali, H; Pola, S; Priyadarshini, P; Sairam, KV; Shah, M; Shah, SR; Sudani, H; Suthar, D; Thube, B; Zaware, P | 1 |
2 other study(ies) available for rosiglitazone and ns-220
| Article | Year |
|---|---|
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation | 2008 |
Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
Topics: Animals; Carboxylic Acids; Cell Line; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Oximes; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Wistar; Structure-Activity Relationship | 2011 |